A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee

Trial Profile

A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Autologous chondrocyte implantation (Primary)
  • Indications Cartilage disorders; Knee injuries
  • Focus Registrational; Therapeutic Use
  • Sponsors Histogenics Corporation
  • Most Recent Events

    • 27 Jun 2017 According to a Histogenics media release, top-line 1-year superiority data expected in the third quarter of 2018, followed by a potential Biologics License Application (BLA) filing.
    • 27 Jun 2017 Status changed from recruiting to active, no longer recruiting, as reported in a Histogenics Corporation media release.
    • 10 Nov 2016 According to a Histogenics media release, more than three-quarters of the 245 patients (75% enrolment) has been enrolled in this trial. As of November 9, 2016 186 of the the 245 patients required under the Special Protocol Assessment (SPA) with the U.S. FDA has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top